You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC,Camrelizumab,SBRT,oligometastatic

Showing 1 - 25 of 4,406
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Metastatic Trial in Chengdu (Camrelizumab, stereotactic body radiation therapy, Chemotherapy)

Recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital & Institute
Jul 21, 2022

Non Small Cell Lung Cancer Trial in Ostrava (Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT),

Recruiting
  • Non Small Cell Lung Cancer
  • Chemotherapy
  • +2 more
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Dec 19, 2022

NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage IV
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 21, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab, gemcitabin, cisplatin
  • Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jun 19, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (camrelizumab, stereotactic body radiotherapy)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 28, 2021

TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in United States (Sterotactic Body

Active, not recruiting
  • TNBC - Triple-Negative Breast Cancer
  • +6 more
  • Sterotactic Body Radiotherapy/SBRT
  • Standard of care
  • Basking Ridge, New Jersey
  • +8 more
Jul 26, 2022

NSCLC Trial (Durvalumab, the first line chemo for metastatic NSCLC, stereotactic body radiotherapy (SBRT))

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Feb 2, 2020

NSCLC Trial in Ostrava (primary tumour radiotherapy, stereotactic body radiotherapy, maintenance radiotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • primary tumour radiotherapy
  • +2 more
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Dec 6, 2022

Solid Tumor Trial in Chicago (Stereotactic body radiotherapy (SBRT), Pembrolizumab)

Active, not recruiting
  • Solid Tumor
  • Chicago, Illinois
    University of Chicago
Mar 14, 2022

EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

Not yet recruiting
  • EGF-R Positive Non-Small Cell Lung Cancer
  • +4 more
  • Stereotactic Body Radiation Therapy SBRT
  • Bogotá, Colombia
    CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
Aug 16, 2023

Esophageal Cancer Trial in Hangzhou (Radiotherapy group, Camrelizumab, Chemotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Radiotherapy group
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 21, 2021

Stage IV NSCLC Trial in Dallas (Stereotactic Body Radiation Therapy, Maintenance chemo)

Completed
  • Stage IV Non-Small Cell Lung Cancer
  • Stereotactic Body Radiation Therapy
  • Maintenance chemotherapy
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 30, 2022

NSCLC Stage IV Trial in Hangzhou (SBRT)

Recruiting
  • NSCLC Stage IV
  • SBRT
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 22, 2022

Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)

Not yet recruiting
  • Oligometastatic Hormone Sensitive Prostate Cancer
  • SBRT on all sites of metastatic disease+Apalutamide
  • Florence, Italy
    AOU Careggi Radiation Oncology Unit
Jan 29, 2023

NSCLC Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1) Trial in Boston (SBRT with protons or photons)

Active, not recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Targetable Oncogenes (EGFR, ALK, ROS1)
  • SBRT with protons or photons
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 22, 2021

Non Small Cell Lung Cancer Trial in Sweden (Standard systemic therapy + radiotherapy, Standard systemic therapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Standard systemic therapy + radiotherapy
  • Standard systemic therapy
  • Gothenburg, Sweden
  • +5 more
Nov 17, 2023

Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Niraparib oral capsule
  • SBRT
  • Sutton, Surrey, United Kingdom
  • +1 more
Aug 10, 2023

NSCLC Trial in Wuhan (Camrelizumab, Apatinib, Docetaxel injection)

Recruiting
  • Non-Small Cell Lung Cancer
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 29, 2022

Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Oligometastatic Disease
  • SBRT plus tislelizumab and regorafenib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2023

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Oligometastatic Disease
  • PD-1 combined with SBRT
  • Guangzhou, Guangdong, China
    Mian Xi
Dec 18, 2022

Treatment Trial in Shanghai (ADT, SBRT)

Recruiting
  • Treatment
  • Shanghai, Shanghai, China
    Changhai hospital
Aug 9, 2022

NSCLC, Stage IV, Oligometastasis Trial in Netherlands, Spain, Switzerland (drug, radiation, procedure)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Milano, Italy
  • +12 more
Dec 14, 2022

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving

Recruiting
  • Non-small Cell Lung Cancer
  • Oligometastatic Disease
  • ctDNA testing and whole exome sequencing
  • Guangzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 5, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer Trial in United States (Stereotactic body

Recruiting
  • Oligometastatic Breast Carcinoma
  • +5 more
  • Stereotactic body radiotherapy
  • Basking Ridge, New Jersey
  • +6 more
Sep 6, 2022